Lymphoma - Featured Clinical Trials
The following list shows Featured Clinical Trials for a specific type of cancer. You may also want to view:
- Dose-adjusted Chemotherapy for Untreated c-MYC-positive Lymphomas
(Posted: 01/25/2011) - In this trial, adult patients with newly diagnosed Burkitt lymphoma or c-MYC-positive diffuse large B-cell lymphoma will be separated into low-risk and high-risk groups; those in the low-risk group will be treated with at least three cycles of dose-adjusted EPOCH-R chemotherapy, while high-risk patients will receive six cycles.
- Vaccine Therapy for Patients with Recurrent Blood Cancers
(Posted: 05/04/2010) - In this phase I/II trial, patients with blood cancer that has recurred after allogeneic stem cell transplantation will be treated with donor T-lymphocyte infusions and a dendritic cell vaccine that is designed to trigger an immune response against cells producing a protein called Wilms tumor 1 (WT1).
- Extending Targeted Immune Depletion to Unrelated Cord Blood Transplantation
(Posted: 03/09/2010) - In this pilot study, patients with leukemia, lymphoma, multiple myeloma, or certain premalignant blood disorders (such as myelodysplastic syndromes) will undergo targeted immune-depleting chemotherapy followed by unrelated double cord blood transplant.
- PARP Inhibitor and Metronomic Chemotherapy for Refractory Cancer
(Posted: 01/12/2010) - In this clinical trial, patients with solid tumors or lymphomas that have not responded to previous treatment (refractory cancer), or for which no effective treatment exists, will receive the PARP inhibitor ABT-888 and metronomic cyclophosphamide.
- Comparing Drug Regimens for Diffuse Large B-cell Lymphoma
(Posted: 09/22/2009) - In this trial, patients with previously untreated diffuse large B-cell lymphoma will be randomly assigned to receive either the R-CHOP regimen or EPOCH-R regimen for 6 to 8 cycles.